Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl ...

ONAPGO, a subcutaneous infusion device, treats motor fluctuations in advanced Parkinson's disease and launches in the U.S. in 2025. Supernus Pharmaceuticals has announced the FDA approval of ...

Supernus will make ONAPGO available in the second quarter of 2025 with a support team of experts, including a robust nurse education program, and access support at launch. “Continuous ...

SPN-820 was well-tolerated with few adverse events. Earlier this month, the FDA approved Supernus Pharmaceuticals’ ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830 ...

Supernus Pharmaceuticals’ Onapgo provides a continuous infusion of apomorphine to manage “off” periods experienced by Parkinson’s disease patients. Approval of Onapgo comes after the FDA ...

ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease ONAPGO is a wearable subcutaneous ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's disease ONAPGO is a wearable subcutaneous infusion ...